Funda Meric‐Bernstam

105.6k total citations · 15 hit papers
876 papers, 35.9k citations indexed

About

Funda Meric‐Bernstam is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Funda Meric‐Bernstam has authored 876 papers receiving a total of 35.9k indexed citations (citations by other indexed papers that have themselves been cited), including 458 papers in Oncology, 392 papers in Cancer Research and 269 papers in Molecular Biology. Recurrent topics in Funda Meric‐Bernstam's work include Cancer Genomics and Diagnostics (194 papers), Breast Cancer Treatment Studies (178 papers) and HER2/EGFR in Cancer Research (120 papers). Funda Meric‐Bernstam is often cited by papers focused on Cancer Genomics and Diagnostics (194 papers), Breast Cancer Treatment Studies (178 papers) and HER2/EGFR in Cancer Research (120 papers). Funda Meric‐Bernstam collaborates with scholars based in United States, United Kingdom and Spain. Funda Meric‐Bernstam's co-authors include Ana M. González-Angulo, Kelly K. Hunt, Gabriel N. Hortobágyi, Henry M. Kuerer, Gordon B. Mills, Filip Jankú, Gildy V. Babiera, Timothy A. Yap, Elizabeth A. Mittendorf and Merrick I. Ross and has published in prestigious journals such as Nature, Cell and The Lancet.

In The Last Decade

Funda Meric‐Bernstam

836 papers receiving 35.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

PD-L1 Expression in Triple-Negative Breast Cancer

2014 1.1k citations Elizabeth A. Mittendorf, Funda Meric‐Bernstam et al. profile →
Targeting the PI3K pathway in cancer: are we making headway?

2018 787 citations Filip Jankú, Timothy A. Yap et al. profile →
Clonal evolution in breast cancer revealed by single nucleus genome sequencing

2014 711 citations Ken Chen, Funda Meric‐Bernstam et al. profile →
Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

2009 684 citations Funda Meric‐Bernstam, Mien‐Chie Hung et al. profile →
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

2013 525 citations Hiroko Masuda, Keith Baggerly et al. Clinical Cancer Research profile →
Targeting the mTOR Signaling Network for Cancer Therapy

2009 522 citations Funda Meric‐Bernstam, Ana M. González-Angulo profile →
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial

2023 432 citations Funda Meric‐Bernstam et al. profile →
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study

2019 383 citations Funda Meric‐Bernstam, Razelle Kurzrock et al. profile →
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study

2018 357 citations Funda Meric‐Bernstam, Howard A. Burris et al. profile →
Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

2021 251 citations Milind Javle, Razelle Kurzrock et al. profile →
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

2021 240 citations Funda Meric‐Bernstam, Randy F. Sweis et al. Clinical Cancer Research profile →
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

2021 171 citations Funda Meric‐Bernstam, Cinta Hierro et al. Cancer Discovery profile →
Antibody-drug conjugates in lung cancer: dawn of a new era?

2023 80 citations Timothy A. Yap, Funda Meric‐Bernstam et al. profile →
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

2024 68 citations Senthil Damodaran, Funda Meric‐Bernstam et al. profile →
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study

2024 43 citations Funda Meric‐Bernstam et al. profile →

Peers

Countries citing papers authored by Funda Meric‐Bernstam

Since Specialization

Citations

This map shows the geographic impact of Funda Meric‐Bernstam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Funda Meric‐Bernstam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Funda Meric‐Bernstam more than expected).

Fields of papers citing papers by Funda Meric‐Bernstam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Funda Meric‐Bernstam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Funda Meric‐Bernstam. The network helps show where Funda Meric‐Bernstam may publish in the future.

Co-authorship network of co-authors of Funda Meric‐Bernstam

This figure shows the co-authorship network connecting the top 25 collaborators of Funda Meric‐Bernstam. A scholar is included among the top collaborators of Funda Meric‐Bernstam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Funda Meric‐Bernstam. Funda Meric‐Bernstam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing 2023 ·SHILAP Revista de lepidopterología ·(unknown), Molly S. Daniels, (unknown), Ecaterina E. Dumbrava, Ying Yuan, Keyur P. Patel, (unknown), (unknown), Chetna Wathoo, (unknown), (unknown), Wanlin Wang, Chacha Horombe, Milind Javle, Jordi Rodón, Timothy A. Yap, Banu Arun, Karen H. Lu, Funda Meric‐Bernstam	1
2	Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor–Positive Metastatic Breast Cancers 2023 ·Cancer Research ·Juliana Navarro-Yepes, Nicole M. Kettner, Xiayu Rao, (unknown), Tuyen Bui, Hannah F. Wingate, Akshara Singareeka Raghavendra, (unknown), Jing Wang, Ayşegül A. Şahin, Funda Meric‐Bernstam, Kelly K. Hunt, Senthil Damodaran, Debu Tripathy, Khandan Keyomarsi	24
3	Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas breakdown → 2021 ·Clinical Cancer Research ·Funda Meric‐Bernstam, Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H.I. Andtbacka, Matthew Ingham, Nancy Lewis, Xinhui Chen, Marc R. Pelletier, Xueying Chen, Jincheng Wu, Thomas W. Dubensky, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Jason J. Luke	240
4	A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations 2019 ·Clinical Cancer Research ·Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric‐Bernstam, Josep Tabernero, Filip Jankú, Leena Gandhi, A. John Iafrate, Darrell R. Borger, Nobuya Ishii, Youyou Hu, (unknown), Valerie Nicolas‐Métral, (unknown), Anne Vaslin Chessex, Claudio Zanna, Keith T. Flaherty, José Baselga	102
5	Prospective Clinical Sequencing of Adult Glioma 2019 ·Molecular Cancer Therapeutics ·Siyuan Zheng, Kristin Alfaro-Munoz, Wei Wei, Xiaojing Wang, Fang Wang, Agda Karina Eterovic, Kenna Shaw, Funda Meric‐Bernstam, Gregory N. Fuller, Ken Chen, Roel G.W. Verhaak, Gordon B. Mills, W. K. Alfred Yung, Shiao-Pei Weathers, John de Groot	15
6	Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition 2018 ·Clinical Cancer Research ·Xian Chen, (unknown), Angela Alexander, Yufeng Jiang, Cansu Karakaş, Kenneth R. Hess, Jason P.W. Carey, Tuyen Bui, Smruthi Vijayaraghavan, Kurt W. Evans, Min Yi, (unknown), Kwok‐Leung Cheung, Ian O. Ellis, Siqing Fu, Funda Meric‐Bernstam, Kelly K. Hunt, Khandan Keyomarsi	78
7	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma 2018 ·Clinical Cancer Research ·David S. Hong, Kathleen N. Moore, Manish R. Patel, Stefan C. Grant, Howard A. Burris, William N. William, Suzanne F. Jones, Funda Meric‐Bernstam, Jeffrey R. Infante, (unknown), Wei Zhang, Ricardo Martínez, Sameera R. Wijayawardana, Richard P. Beckmann, Aimee Bence Lin, Cathy Eng, Johanna C. Bendell	62
8	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer 2017 ·Cancer Discovery ·John H. Strickler, Jonathan M. Loree, Leanne G. Ahronian, Aparna R. Parikh, Donna Niedzwiecki, Allan Andresson Lima Pereira, Matthew McKinney, W. Michael Korn, Chloé E. Atreya, Kimberly C. Banks, Rebecca J. Nagy, Funda Meric‐Bernstam, Richard B. Lanman, AmirAli Talasaz, Igor F. Tsigelny, Ryan B. Corcoran, Scott Kopetz	196
9	Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual 2016 ·Clinical Cancer Research ·Chad Tang, Kenneth R. Hess, (unknown), Suzanne E. Davis, Aman U. Buzdar, Razelle Kurzrock, J. Jack Lee, Funda Meric‐Bernstam, David S. Hong	9
10	High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype 2016 ·Clinical Cancer Research ·Jennifer B. Dennison, Maria Shahmoradgoli, Wenbin Liu, Zhenlin Ju, Funda Meric‐Bernstam, Charles M. Perou, Ayşegül A. Şahin, Alana L. Welm, Steffi Oesterreich, Matthew J. Sikora, Robert Brown, Gordon B. Mills	26
11	mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer 2015 ·Clinical Cancer Research ·Wei Mo, Qingxin Liu, Curtis Chun-Jen Lin, Hui Dai, Yang Peng, Yulong Liang, Guang Peng, Funda Meric‐Bernstam, Gordon B. Mills, Kaiyi Li, Shiaw‐Yih Lin	90
12	Influence of Biospecimen Variables on Proteomic Biomarkers in Breast Cancer 2014 ·Clinical Cancer Research ·Funda Meric‐Bernstam, Argun Akçakanat, Huiqin Chen, Ayşegül A. Şahin, Emily Tarco, Selin Çarkaci, Beatriz E. Adrada, Gopal K. Singh, Kim‐Anh Do, (unknown), Elizabeth A. Mittendorf, Gildy V. Babiera, Isabelle Bedrosian, Rosa F. Hwang, Savitri Krishnamurthy, W. Fraser Symmans, Ana M. González-Angulo, Gordon B. Mills	40
13	Weekly nab -Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial 2013 ·Clinical Cancer Research ·Ana M. González-Angulo, Funda Meric‐Bernstam, Sant P. Chawla, Gerald S. Falchook, David S. Hong, Argun Akçakanat, Huiqin Chen, Aung Naing, Siqing Fu, Jennifer J. Wheler, Stacy Moulder, Thorunn Helgason, Shaoyi Li, Ileana Elias, Neil Desai, Razelle Kurzrock	63
14	Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes breakdown → 2013 ·Clinical Cancer Research ·Hiroko Masuda, Keith Baggerly, Ying Wang, Ya Zhang, Ana M. González-Angulo, Funda Meric‐Bernstam, Vicente Valero, Brian D. Lehmann, Jennifer A. Pietenpol, Gabriel N. Hortobágyi, W. Fraser Symmans, Naoto T. Ueno	525
15	Accelerated Approval and Breakthrough Therapy Designation: Oncology Drug Development on Speed? 2013 ·Clinical Cancer Research ·James C. Yao, Funda Meric‐Bernstam, J. Jack Lee, Sabine Eckhardt	8
16	Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer 2012 ·Clinical Cancer Research ·Takafumi Sangai, Argun Akçakanat, Huiqin Chen, Emily Tarco, Yun Wu, Kim‐Anh Do, Todd W. Miller, Carlos L. Arteaga, Gordon B. Mills, Ana M. González-Angulo, Funda Meric‐Bernstam	124
17	A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer 2011 ·Clinical Cancer Research ·David S. Hong, Razelle Kurzrock, Yun Oh, Jennifer J. Wheler, Aung Naing, Les Brail, Sophie Callies, Valérie André, Sunil Kadam, Aejaz Nasir, Timothy R. Holzer, Funda Meric‐Bernstam, Mayer Fishman, George R. Simon	113
18	Rapamycin Regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer 2010 ·Molecular Cancer Therapeutics ·David Luyimbazi, Argun Akçakanat, Priscilla F. McAuliffe, Li Zhang, Gopal K. Singh, Ana M. González-Angulo, Huiqin Chen, Kim‐Anh Do, Yuhuan Zheng, Mien‐Chie Hung, Gordon B. Mills, Funda Meric‐Bernstam	60
19	High Prevalence of Preinvasive Lesions Adjacent to BRCA1/2-Associated Breast Cancers 2009 ·Cancer Prevention Research ·Banu Arun, Kristen J. Vogel, Adriana López, Mike Hernández, (unknown), Kristine Broglio, Christopher I. Amos, Funda Meric‐Bernstam, Henry M. Kuerer, Gabriel N. Hortobágyi, Constance T. Albarracin	21
20	Prognostic Value of Initial Clinical Disease Stage After Achieving Pathological Complete Response 2008 ·The Oncologist ·Shaheenah Dawood, Kristine Broglio, Shu‐Wan Kau, Rabiul Islam, W. Fraser Symmans, Thomas A. Buchholz, Sean E. McGuire, Funda Meric‐Bernstam, Massimo Cristofanilli, Gabriel N. Hortobágyi, Ana M. González-Angulo	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact